復方丹參片聯(lián)合苯磺酸氨氯地平片治療H型高血壓頸動脈粥樣硬化的臨床研究

打開文本圖片集

[Abstract]Objective：To investigate the clinical effect ofcombined treatment with Fufang Danshen Tablets combined withAmlodipineBesylateTabletsforcarotidatherosclerosis （CAS）inH-type hypertension.Method： Sixty-two patients with H-type hypertensionand CAS who were admittedto Fuzhou Jianqiang Fifth Hospitalfrom August 2022 to August 2O24 were selected and divided into the control group and the observation group byrandom number table method，with 31 cases in each group.Allpatients were given conventional treatment.The control group was treated with Amlodipine Besylate Tablets，and the observation group was treated with Fufang Danshen Tablets based on the treatment inthe control group.The two groups were comparedoncurativeeffct，blood lipids indicators，ultrasound indicators，and the incidence of adverse reactions was calculated.Result： The total effective rateof treatment in the observation group was higher than that in the control group，the difference was statistically significant （ P <0.05）.After treatment，the high-density lipoprotein cholesterol in the observation group was higherthan thatin the control group， whilethe low-density lipoproteincholesterol，triglycerides，homocysteine，carotid intima-media thickness，and plaque area were allower in the observation group than those in the control group，the diferences werestatistically significant （ P<0.05） .Conclusion： The combined treatment with Fufang Danshen Tablets combined with Amlodipine Besylate Tablets issafe and effctive for patients with H-type hypertensionandCAS.Itcan effectively control blood pressure and blood lipids，and stabilize plaques.

[KeyWords]Fufang Danshen TabletsAmlodipine Besylate TabletsH-type hypertensionCarotid atherosclerosis

First-author'saddress：Department of Pharmacy，F(xiàn)uzhou Institute of Medical Sciences，F(xiàn)uzhou 344000， China

doi：10.3969/j.issn.1674-4985.2025.21.029

高血壓是一種可治療但需終生控制的疾病，也是引起腦卒中、冠心病等心血管疾病的重要危險因素[]。（剩余5067字）